Bennett Stephen, Gronier Benjamin
School of Pharmacy, De Montfort University, The Gateway, Leicester, United Kingdom.
Synapse. 2007 Aug;61(8):679-88. doi: 10.1002/syn.20413.
The acute administration of the noncompetitive glutamate N-methyl-D-aspartate (NMDA) receptor antagonist dizocilpine (MK 801) is known to increase central dopaminergic activity in rats and to elicit schizophreniform behavior in human. The current study was undertaken to compare the effects of different acute or chronic neuroleptic treatments, on the response of ventral tegmental area dopamine (DA) neurons to MK 801, using the in vivo electrophysiological paradigm in anesthetized preparations. Sprague Dawley male rats were treated, acutely or chronically during 3 weeks, with saline, olanzapine (10 mg/kg), haloperidol (1 mg/kg) or the combination of haloperidol with D-serine (1 mg/kg/300 mg/kg), a gliotransmitter coagonist of the NMDA receptor that has been shown to improve the efficacy of typical neuroleptics. In control animals, the acute administration of MK 801 (0.5 mg/kg, i.v.) increased significantly both the firing and burst activity of DA neurons by 20 and 26%, respectively, the latter effect being partially reversed by the selective 5-HT2A antagonist M 100,907 (0.4 mg/kg, i.v.). The acute preadministration of haloperidol (1 mg/kg, i.p.) and olanzapine (10 mg/kg, i.p.) failed to prevent or reverse the activatory effect of MK 801 on firing activity. On the other hand, MK 801-induced burst activity, was partially prevented by olanzapine, but not by haloperidol pretreatment. All antipsychotic treatments, when administered chronically, prevent the activatory effect of MK 801 on both firing and burst activity, and occasionally convert the response to MK 801 on burst activity to an inhibitory response, the latter occurring more predominantly in rats treated with the combination haloperidol/D-serine. These results suggest that a chronic antipsychotic regime alters the function of the NMDA receptors that tonically control the firing activity of midbrain dopaminergic neurons.
已知非竞争性谷氨酸N-甲基-D-天冬氨酸(NMDA)受体拮抗剂地佐环平(MK 801)的急性给药可增加大鼠的中枢多巴胺能活性,并在人类中引发精神分裂症样行为。本研究旨在使用麻醉制剂中的体内电生理范式,比较不同急性或慢性抗精神病药物治疗对腹侧被盖区多巴胺(DA)神经元对MK 801反应的影响。将Sprague Dawley雄性大鼠在3周内进行急性或慢性治疗,分别给予生理盐水、奥氮平(10 mg/kg)、氟哌啶醇(1 mg/kg)或氟哌啶醇与D-丝氨酸(1 mg/kg/300 mg/kg)的组合,D-丝氨酸是一种NMDA受体的胶质递质协同激动剂,已被证明可提高典型抗精神病药物的疗效。在对照动物中,急性给予MK 801(0.5 mg/kg,静脉注射)可使DA神经元的放电和爆发活动分别显著增加20%和26%,后者的作用可被选择性5-HT2A拮抗剂M 100,907(0.4 mg/kg,静脉注射)部分逆转。急性预先给予氟哌啶醇(1 mg/kg,腹腔注射)和奥氮平(10 mg/kg,腹腔注射)未能预防或逆转MK 801对放电活动的激活作用。另一方面,奥氮平可部分预防MK 801诱导的爆发活动,但氟哌啶醇预处理则不能。所有抗精神病药物治疗在长期给药时,均可预防MK 801对放电和爆发活动的激活作用,偶尔还可将对MK 801爆发活动的反应转变为抑制反应,后者在接受氟哌啶醇/D-丝氨酸组合治疗的大鼠中更为常见。这些结果表明,慢性抗精神病药物治疗可改变对中脑多巴胺能神经元放电活动起紧张性控制作用的NMDA受体的功能。